BioCentury
ARTICLE | Clinical News

CHS-1701: Phase I data

October 12, 2015 7:00 AM UTC

Top-line data from a double-blind, crossover, U.S. Phase I trial in 116 healthy volunteers showed that a single subcutaneous injection of 6 mg CHS-1701 met the primary endpoint of biosimilarity to Ne...